Open AccessPharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age
Author(s) -
Antonio Arrieta,
Jocelyn Y. Ang,
Claudia Espinosa,
О.D. Fofanov,
Camilla Tøndel,
Margaret Z Chou,
Carisa S De Anda,
Jason Y. Kim,
Dan Li,
Philip E. Sabato,
P.S. Sears,
John S. Bradley
Publication year - 2021
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003030
Subject(s) - medicine , pharmacokinetics , dosing , bioavailability , oral administration , adverse effect , pharmacology
Infections with Gram-positive bacteria, including acute bacterial skin and skin structure infections (ABSSSIs), are common in children. We describe a single-dose pharmacokinetics and safety study of tedizolid phosphate, a new oxazolidinone under investigation for the treatment of ABSSSIs in children, in hospitalized participants 2 to <12 years of age.